FBLG shows severe cash burn acceleration with net losses increasing 67% to $18.6M while cash reserves declined 65% to $4.9M, creating potential liquidity concerns despite improved balance sheet structure.
The dramatic increase in R&D spending and operating cash outflows indicates aggressive investment in their fibroblast cell therapy development, but at an unsustainable pace given the depleted cash position. While debt reduction improved the balance sheet structure significantly, the company faces imminent funding needs given current burn rates.
FBLG's financial profile shows a tale of two stories - significant balance sheet deleveraging with liabilities falling 75% and equity more than doubling, but alarming deterioration in operating performance with net losses up 67% and operating cash outflows increasing 38%. The 65% decline in cash to $4.9M combined with accelerating burn rates creates immediate liquidity concerns, while the 64% jump in R&D expenses suggests the company is aggressively investing in late pre-clinical development despite constrained resources. Overall, this represents a high-risk situation where improved capital structure is being offset by unsustainable cash consumption patterns.
Equity base grew 125.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current liabilities reduced — improved short-term financial position and working capital health.
Liabilities reduced 74.7% — deleveraging improves balance sheet strength and financial flexibility.
Net income declined 67.1% — review whether driven by operations, interest costs, or non-recurring items.
Cash declined 65% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
R&D investment increased 64.5% — signals commitment to future product development, though near-term margin impact.
Current assets declined 55.4% — monitor working capital adequacy and short-term liquidity.
Capital expenditure jumped 42.4% — major investment cycle underway; assess returns on deployment.
Total assets contracted 41.5% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow fell 37.8% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →